| Acquisition completion and GTLS delisting | Baker Hughes announced the successful completion of its all-cash acquisition of Chart Industries on July 16, 2026. StockAnalysis marked GTLS delisted on July 16, 2026 for the reason "acquired by BKR", with a last trade of $209.90. | Baker Hughes closing press release and StockAnalysis GTLS quote and history pages | August 3, 2026 |
| Merger consideration and deal structure | The merger agreement provided $210.00 in cash per common share. Baker Hughes targets $325 million in annualized cost synergies by year three after close, and Chart now operates as Baker Hughes third reporting segment led by Jim Apostolides. | Baker Hughes closing press release | August 3, 2026 |
| S&P MidCap 400 index replacement | S&P Dow Jones Indices announced on July 14, 2026 that Chart Industries (GTLS) would be removed from the S&P MidCap 400 effective July 17, 2026, with BrightSpring Health Services replacing it, as Baker Hughes acquired Chart in a deal expected to close July 16. | S&P Dow Jones Indices announcement via PR Newswire | August 3, 2026 |
| Final GTLS price, shares, and market capitalization | $209.90 last trade, 47.87 million shares outstanding, and about $10.05 billion market capitalization at the final quote. Price multiplied by shares equals $10,047.9 million versus reported $10,050 million, a 0.02% variance verified with financial_rigor.py. | StockAnalysis GTLS statistics and financial_rigor.py market-cap verification | August 3, 2026 |
| FY2025 revenue and five-year financial trend | FY2025 revenue was $4,264.0 million, up 2.5% from $4,160.3 million in 2024. StockAnalysis shows revenue of $1,318 million in 2021, $1,612 million in 2022, $3,353 million in 2023, $4,160 million in 2024, and $4,264 million in 2025. | Chart Industries 2025 Form 10-K and StockAnalysis financials | August 3, 2026 |
| FY2025 profitability, adjusted earnings, and free cash flow | GAAP net income attributable to Chart was $40.7 million, adjusted EPS was $9.72, adjusted EBITDA was $1,014.3 million, and continuing-operations free cash flow was $204.8 million. The reported GAAP result included a $266.0 million Flowserve termination fee expense. | Chart Industries Q4 and full-year 2025 results release | August 3, 2026 |
| Q1 2026 operating results and backlog | Sales were $884.8 million versus $1,001.5 million in Q1 2025, net loss attributable to Chart was $17.1 million, cash used in continuing operations was $248.0 million, and backlog was $6,282.9 million versus $5,143.6 million a year earlier. | Chart Industries Form 10-Q for the quarter ended March 31, 2026 | August 3, 2026 |
| Cash, debt, and balance-sheet position | March 31, 2026 cash and cash equivalents were $267.9 million, total debt net of issuance costs was $3,786.8 million, and long-term debt was $3,786.7 million. FY2025 cash was $366.0 million and long-term debt was $3,565.0 million. | Chart Industries Q1 2026 Form 10-Q, FY2025 Form 10-K, and StockAnalysis balance sheet | August 3, 2026 |
| European Commission approval and closing status | The European Commission conditionally approved the acquisition on July 10, 2026 after Baker Hughes offered remedies, and Baker Hughes completed the transaction on July 16, 2026. All material closing conditions were satisfied. | Reuters EU decision report and Baker Hughes closing release | August 3, 2026 |
| BKR successor reference and Q2 2026 context | Baker Hughes closed at $60.49 on July 31, 2026, with a market cap of about $60.05 billion. Q2 2026 orders were $10.5 billion, revenue was $6.7 billion, adjusted EPS was $0.64, and the Chart acquisition was completed in July 2026. | StockAnalysis BKR quote and Baker Hughes Q2 2026 results release | August 3, 2026 |
| Final technical reference statistics | 50-day moving average $208.02, 200-day moving average $205.87, RSI 68.29, 20-day average volume about 1.34 million shares, beta 1.53, and 52-week price change +26.15%. | StockAnalysis GTLS statistics page | August 3, 2026 |